Polyrizon (PLRZ) highlights positive pre-clinical allergen-blocking data for PL-14 in Form 6-K

Rhea-AI Filing Summary

Polyrizon Ltd. furnished a Form 6-K as a foreign private issuer, providing a press release dated October 6, 2025. The release is titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy,” indicating that PL-14 showed encouraging allergen-blocking performance in pre-clinical testing. The first five paragraphs of this press release are expressly incorporated by reference into Polyrizon’s effective employee equity Registration Statements on Form S-8, making the scientific update part of those registration statements from the date of this filing.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

Report of Foreign Private Issuer

Pursuant to Rule 13a-16 or 15d-16

under the Securities Exchange Act of 1934

For the month of October 2025

Commission file number: 001-42375

Polyrizon Ltd.

(Translation of registrant’s name into English)

5 Ha-Tidhar Street

Raanana, 4366507, Israel

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

CONTENTS

Attached hereto and incorporated herein is the Registrant’s press release issued on October 6, 2025, titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy.”

The first five paragraphs of the press release attached to this Report of Foreign Private Issuer on Form 6-K as Exhibit 99.1 are incorporated by reference into the Registrant’s Registration Statements on Form S-8 (File No. 333-284410 and 333-288923), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

EXHIBIT INDEX

Exhibit No.
99.1		Press release titled: “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy”

1

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Polyrizon Ltd.
Date: October 6, 2025	By:	/s/ Tomer Izraeli
	Name:	Tomer Izraeli
	Title:	Chief Executive Officer

2

FAQ

What did Polyrizon Ltd. (PLRZ) report in its latest Form 6-K?

Polyrizon Ltd. furnished a Form 6-K that attaches a press release titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy,” highlighting encouraging pre-clinical performance of PL-14.

What is the main focus of Polyrizon’s October 6, 2025 press release?

The press release focuses on positive pre-clinical results for Polyrizon’s product candidate PL-14, which demonstrated encouraging allergen-blocking efficacy in pre-clinical testing.

How does this Form 6-K affect Polyrizon’s Form S-8 registration statements?

The filing states that the first five paragraphs of the October 6, 2025 press release are incorporated by reference into Polyrizon’s existing Form S-8 Registration Statements (File Nos. 333-284410 and 333-288923).

Which registration statements are updated by this Polyrizon 6-K filing?

The Form 6-K incorporates the press release into Polyrizon’s Form S-8 Registration Statements with file numbers 333-284410 and 333-288923 filed with the SEC.

Who signed the October 6, 2025 Form 6-K for Polyrizon Ltd.?

The Form 6-K was signed on behalf of Polyrizon Ltd. by Tomer Izraeli, who is identified as the company’s Chief Executive Officer.

What exhibit is attached to Polyrizon Ltd.’s October 2025 Form 6-K?

The Form 6-K includes Exhibit 99.1, which is the press release titled “Polyrizon Announces Positive Pre-Clinical Results: PL-14 Demonstrates Encouraging Allergen-Blocking Efficacy.”